SCHEMBL6715541

SCHEMBL6715541

Cc1ccccc1NC(=O)C(NC(=S)Nc1ccccc1)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ULK1 O75385 1/20 0.50
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
LMNA P02545 4/20 0.48
ALDH1A1 P00352 3/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
GAA P10253 1/20 0.48
HPGD P15428 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HTT P42858 2/20 0.47
ALOX12 P18054 2/20 0.47
MAPT P10636 2/20 0.47
EPHX1 P07099 2/20 0.47
DDX3X O00571 1/20 0.47
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6718043 0.92 ULK1 (0.56) ULK1CA1CA2LMNAALDH1A1
SCHEMBL6719552 0.91 CYP1A2 (0.52) CA1CA2LMNAALDH1A1MEN1
SCHEMBL6714044 0.89 MAPT (0.61) ULK1CA1CA2LMNAALDH1A1
SCHEMBL6715567 0.89 ULK1 (0.56) ULK1LMNAMEN1KMT2AGAA
SCHEMBL6713819 0.87 IMPDH2 (0.47) ULK1CA1CA2LMNAALDH1A1
SCHEMBL6726995 0.87 CRHBP (0.55) ULK1LMNAALDH1A1MEN1KMT2A
SCHEMBL6719158 0.86 ULK1 (0.61) ULK1LMNAALDH1A1MEN1KMT2A
SCHEMBL6727015 0.84 CYP1A2 (0.53) LMNAALDH1A1MEN1KMT2AGAA
SCHEMBL6713927 0.84 MAPT (0.49) LMNAALDH1A1MEN1KMT2AGAA
SCHEMBL6719258 0.84 KMT2A (0.51) LMNAALDH1A1MEN1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed
WO-2004022528-A2 ARYLGLYCINE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed
WO-2004022528-A2 ARYLGLYCINE DERIVATIVES AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 ULK1 3906/4885CA1 1260/4885CA2 988/4885
US-20040152741-A1 Arylglycine derivatives and their use as glycine transport inhibitors SLC1A2, SLC1A1, SLC7A11 ULK1 3524/4885CA1 1682/4885CA2 1403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.